Skip to content

Inspection Record

Duke University — FDA 483 Findings

US FDAInspected 2019-08-02Published 2026-10-30 11 findingsDeviation, CAPA, and investigationMaterial and supplier controlOther quality systemComputer system validationEnvironmental monitoringQuality unit oversightAseptic processing and sterility assuranceDocumentation and recordsContamination control

Inspectors Team Lead · Sukhanya JayachandraThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Deviation, CAPA, and investigation

Report # DEV-0723 019 documented a deviation for GMP lots GMP-™@, Gmp-®4 Gopwhere final product mycoplasma test results provided by contract testing lab were determined by the contract lab to be invalid.

2Material and supplier control

The inventory control of raw materials is deficient.

3Other quality system

The existing alarm system and its implementation are deficient.

4Computer system validation

A means of assuring data protection has not been established for the following computerized system.

5Environmental monitoring

The environmental monitoring program is deficient in ensuring that the cleanrooms are operating in a state of environmental control.

6Quality unit oversight

The Quality Unit does not have adequate contro] over critical materials.

7Aseptic processing and sterility assurance

Performance qualification (PQ) of numerous critical equipment was not completed prior to conducting process performance qualification runs (November 16, 2018 — January 17, 2019) and aseptic processing runs (August 2018).

8Deviation, CAPA, and investigation

Corrective actions and preventive actions (CAPA) implemented are not always being documented per the CAPA SOP COMM-QA-076.

9Documentation and records

The Quality Unit oversight of batch record review is deficient.

10Contamination control

Procedures and process contro] designed to prevent microbiological contamination of drug product are not established with appropriate acceptance criteria.

11Environmental monitoring

The current cleaning procedures used in the cleanroom have not been qualified.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-30. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Duke University company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.